ARTICLE | Company News
Aegera, LymphoSign deal
August 13, 2007 7:00 AM UTC
Aegera acquired LymphoSign for an undisclosed price. Aegera receives LymphoSign's LS104, a multiple tyrosine kinase inhibitor in Phase I testing to treat acute myelogenous leukemia (AML) and other mye...